Adalimumab/etanerceptInflammatory bowel disease: 7 case reports

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2008年 / 1197卷 / 1期

关键词：

Public Health; Rheumatoid Arthritis; Arthritis; Inflammatory Bowel Disease; Patient Outcome;

D O I：

10.2165/00128415-200811970-00013

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：5 / 5

相关论文

共 50 条

[1] EtanerceptInflammatory bowel disease: 4 case reports
Reactions Weekly, 2020, 1795 (1) : 127 - 127
[2] EtanerceptInflammatory bowel disease: 8 case reports
Reactions Weekly, 2011, 1347 (1) : 20 - 20
[3] EtanerceptInflammatory bowel disease: 9 case reports
Reactions Weekly, 2016, 1583 (1) : 464 - 464
[4] EtanerceptInflammatory bowel disease: 3 case reports
Reactions Weekly, 2017, 1668 (1) : 177 - 177
[5] EtanerceptInflammatory bowel syndrome: 13 case reports
Reactions Weekly, 2011, 1368 (1) : 18 - 18
[6] EtanerceptInflammatory bowel disease: case report
Reactions Weekly, 2025, 2040 (1) : 367 - 367
[7] Adalimumab/etanercept/infliximabMalignancy: 7 case reports
Reactions Weekly, 2015, 1565 (1) : 19 - 19
[8] Adalimumab/tocilizumabLack of efficacy: 7 case reports
Reactions Weekly, 2023, 1967 (1) : 23 - 23
[9] Adalimumab/infliximabVarious toxicities: 7 case reports
Reactions Weekly, 2018, 1707 (1) : 19 - 19
[10] Adalimumab/etanercept/infliximabBronchospasm: 7 case reports
Reactions Weekly, 2009, 1272 (1) : 5 - 6

← 1 2 3 4 5 →